Acciones Diaxonhit Euronext Paris
Acciones
FR0004054427
Biotecnología e investigación médica
Ventas 2023 | 130 M 139 M | Ventas 2024 * | 138 M 148 M | Capitalización | 145 M 155 M |
---|---|---|---|---|---|
Resultado Neto 2023 | 4 M 4,28 M | Resultado Neto 2024 * | 9 M 9,62 M | VE / Ventas 2023 | 1,29 x |
Deuda neta 2023 * | 8,8 M 9,41 M | Posición de caja neta 2024 * | 9,9 M 10,58 M | VE / Ventas 2024 * | 0,98 x |
P/E ratio 2023 |
38,3
x | P/E ratio 2024 * |
15
x | Empleados | - |
Rendimiento 2023 * |
-
| Rendimiento 2024 * |
-
| Flotante | 59,14 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/06/17 |
Director of Finance/CFO | 43 | 01/10/22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/06/17 |
Director/Board Member | 68 | 04/11/09 | |
Director/Board Member | 67 | 15/06/17 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+0,96 % | 42,86 mil M | |
+13,63 % | 42,74 mil M | |
+44,98 % | 41,36 mil M | |
-6,20 % | 27,68 mil M | |
+6,54 % | 25,15 mil M | |
-23,50 % | 18,63 mil M | |
+29,55 % | 12,37 mil M | |
-2,92 % | 11,92 mil M | |
+7,11 % | 11,21 mil M |